Galenica AG (0ROG.L) Bundle
From a 1927 founding by 16 pharmacists to a modern healthcare and logistics powerhouse, Galenica AG has grown into a cornerstone of Swiss healthcare: founded in 1927 as Collaboration Pharmaceutique SA and rebranded in 1932 as Galenica AG, the group expanded through strategic acquisitions (Panpharma 1957, Hausmann AG in the 1980s) and product innovations such as Venofer and Maltofer, evolving into a company that reported roughly CHF 4 billion in revenues in 2022 and employs over 7,600 people; publicly listed on the SIX under 0ROG, Galenica now runs two core segments - Products & Care (pharmacy network, home care services, professional services and, since September 2025, the diagnostic capabilities of Labor Team) and Logistics & IT (wholesale distribution and digital solutions) - generating income from retail drug sales, wholesale distribution, services like vaccinations and consultations, proprietary brands, and third‑party logistics/IT contracts, while recent performance shows sales up 4.7% to CHF 1,314.2 million in the first four months of 2025 and management targets 3-5% sales growth with 4-6% EBIT growth for 2025, underscoring a diversified, institutionally backed ownership structure and governance that supports continued investment in innovation, sustainability and integrated care.
Galenica AG (0ROG.L): Intro
Galenica AG traces its roots to 1927 when 16 Swiss pharmacists founded Collaboration Pharmaceutique SA in Clarens to centralize purchasing of pharmaceutical products. In 1932 the company adopted the name Galenica AG and moved its headquarters to Bern, beginning a gradual national expansion. Strategic acquisitions and product development shaped the group across decades:- 1957: Acquisition of Panpharma AG, establishing a foundation for pharmaceutical activities.
- 1977: Publication of the Codex Galenica, Switzerland's first comprehensive list of medicines.
- 1980s: Acquisition of Hausmann AG laboratories; expansion into iron-deficiency treatments including Venofer and Maltofer.
- By 2022: Evolved into a leading Swiss healthcare and logistics group with revenues ≈ CHF 4.0 billion and >7,600 employees.
- Listed company: Galenica AG is publicly traded on the Swiss exchange (SIX).
- Shareholder base: broadly held by institutional investors (pension funds, asset managers) and retail investors; no single controlling family listed publicly.
- Governance: traditional Swiss corporate governance with a Board of Directors and Executive Management responsible for retail, wholesale/logistics and healthcare services operations.
- Mission: Improve patient access to medicines and health services across Switzerland through an integrated network of pharmacies, logistics and healthcare solutions (see detailed statement: Mission Statement, Vision, & Core Values (2026) of Galenica AG.).
- Strategic pillars: pharmacy retail leadership, end‑to‑end pharmaceutical logistics, value-added healthcare services and partnerships with manufacturers and payors.
- Retail network: operates branded and franchised community pharmacies offering dispensing, advice, OTC sales and in‑store services (vaccination, screenings, adherence programs).
- Wholesale & logistics: central distribution and cold‑chain logistics for pharmacies, hospitals and manufacturers; inventory management and B2B order fulfilment.
- Healthcare services & solutions: clinical services, digital adherence tools, specialty pharmacy services and contract services for pharma clients.
- Pharmacy retail margins: gross margin generated from OTC and prescription dispensing; service revenues (vaccinations, counseling) add incremental margin and footfall.
- Wholesale/Logistics: volume‑driven, lower gross margins but high recurring cash conversion due to B2B contracts and distribution scale.
- Value‑added services: higher‑margin offerings (specialty pharmacy, clinical programs, digital services) aimed at margin uplift and customer lock‑in.
- Pricing & reimbursement: revenues for prescription medicines are influenced by Swiss reimbursement rules and negotiated margins with payors and authorities.
| Metric | Value (2022) |
|---|---|
| Total revenues | ≈ CHF 4.0 billion |
| Employees | > 7,600 |
| Headquarters | Bern, Switzerland |
| Founding year | 1927 |
| Core segments | Retail pharmacies; Wholesale & Logistics; Healthcare services & solutions |
- Revenue resilience stems from staple nature of pharmaceuticals and service diversification (retail + logistics + services).
- Margin expansion opportunities: scaling specialty services and digital health offerings; efficiency gains in centralized logistics.
- Regulatory exposure: pricing and reimbursement policy in Switzerland materially affect pharmacy and wholesale economics.
- Capital allocation: investments in IT, cold‑chain logistics and service capability to capture higher‑margin healthcare services.
Galenica AG (0ROG.L): History
Galenica AG (0ROG.L) traces its roots to Swiss pharmacy and healthcare services dating back several decades, evolving from a local wholesaler and retail pharmacy chain into an integrated healthcare-services group focused on pharmacy retail, wholesale logistics and patient services. Strategic acquisitions and a steady dividend policy have underpinned investor confidence and a relatively stable ownership profile through the 2010s and early 2020s. Galenica AG: History, Ownership, Mission, How It Works & Makes Money Ownership Structure- Listed on the SIX Swiss Exchange under ticker 0ROG, Galenica AG's shares are widely available to institutional and retail investors.
- Shareholder base is diversified: Swiss pension funds, international investment firms, private individuals and company insiders.
- As of 2022, major institutional holders (including Swiss pension funds and foreign asset managers) accounted for the bulk of the top holdings, with the top 10 shareholders representing roughly 40-50% of the free float.
- Board and executive leadership: Markus R. Neuhaus (Chairman) and Marc Werner (CEO) provide governance and operational leadership, supported by an experienced Board of Directors and senior management team.
- Ownership and governance have shown relative stability in recent years, with no material hostile moves or major control changes reported.
| Item | Detail |
|---|---|
| Exchange / Ticker | SIX Swiss Exchange / 0ROG |
| Largest shareholder groups (2022) | Swiss pension funds, international investment firms, founding/private investors |
| Top 10 shareholders (approx. share of free float) | ~40-50% |
| Chairman | Markus R. Neuhaus |
| CEO | Marc Werner |
| Governance focus | Alignment of shareholder and management interests, transparency, accountability |
| Recent ownership changes | Relatively stable; no significant shifts announced in 2020-2022 |
Galenica AG (0ROG.L): Ownership Structure
Galenica AG (0ROG.L) pursues a mission to enhance health and well-being in Switzerland by providing comprehensive healthcare services and products. The group's values emphasize innovation, sustainability, customer-centricity, integrity and ethical conduct, and collaboration with healthcare professionals and organizations to deliver integrated care solutions. For an official articulation of these principles see: Mission Statement, Vision, & Core Values (2026) of Galenica AG.- Mission: Enhance health and well‑being in Switzerland through integrated healthcare services and products.
- Innovation: Invests in new care models, digital health and product development to meet evolving patient needs.
- Sustainability: Implements eco‑friendly practices across distribution, retail and logistics operations to reduce environmental footprint.
- Customer‑centricity: Focus on high‑quality services (pharmacy, home care, digital) that improve patient outcomes and access.
- Integrity & Ethics: Compliance, data protection and transparent governance are core to trust and reliability.
- Collaboration: Partnerships with clinics, payers and healthcare professionals to deliver integrated care solutions.
| Owner Category | Approx. Stake | Notes |
|---|---|---|
| Institutional investors | ~45% | Pension funds, asset managers active in Swiss equity markets |
| Retail / Free float | ~30% | Swiss and international private investors via SIX/LSE listings |
| Strategic / Corporate holdings | ~15% | Healthcare partners, long‑term collaborators |
| Founders / Management | ~8% | Board and executive holdings, long‑term alignment |
| Treasury shares | ~2% | Shares held by the company for programs and M&A flexibility |
- Retail pharmacy network: prescription and OTC sales, front‑of‑store products, vaccination and consultative services.
- Health services & logistics: wholesale distribution to pharmacies and healthcare institutions, contract logistics, specialty medicines handling.
- Home care & outpatient services: medication management, home nursing and digital care solutions billed to insurers or patients.
- Pharmaceutical products & generics: manufacture/marketing of proprietary and third‑party medicines and supplements.
- Digital health and B2B platforms: software, data services and platforms enabling providers and payers to improve care pathways.
| Indicator | Value |
|---|---|
| Annual revenue | ~CHF 3.5-4.5 billion |
| Adjusted EBIT / EBITDA | ~CHF 250-450 million (adjusted EBITDA range) |
| Net profit | ~CHF 80-200 million |
| Employees | ~7,000-9,000 |
| Number of pharmacies / retail outlets | ~500-700 locations |
| Geographic focus | Primarily Switzerland (majority), selective international activities |
Galenica AG (0ROG.L): Mission and Values
Galenica AG (0ROG.L) operates as an integrated healthcare group combining retail pharmacy services, care-oriented offerings, wholesale distribution and healthcare IT. Its stated mission centers on improving patient outcomes and accessibility of medicines and care through an end-to-end approach that links points of care, logistics and digital tools. Core values emphasize patient-centricity, reliability, professional expertise and innovation. Mission Statement, Vision, & Core Values (2026) of Galenica AG. How It Works Galenica's structure is designed to cover the entire pharmaceutical value chain from prescription to patient, supported by digital services and wholesale logistics.- Two primary reporting segments: Products & Care, and Logistics & IT.
- Integrated model: retail/pharmacy touchpoints feed demand signals into wholesale and IT systems to optimize supply and patient services.
- Cross-segment synergies: shared IT platforms, centralized procurement and coordinated clinical services improve margins and service levels.
- Network of local pharmacies and Pharmacies at Home providing prescription and OTC products, vaccinations, medication reviews and counseling.
- Services for Professionals: consulting, medication management and advisory services for care homes and home-care organizations.
- After September 2025 acquisition of Labor Team, diagnostic services (lab testing) were integrated into Products & Care to broaden clinical services and point-of-care diagnostics.
- Wholesale distribution: national supply chain management, centralized warehouses and last-mile delivery to pharmacies, hospitals and care providers.
- IT services: pharmacy management systems, e-prescription integration, inventory optimization and third‑party software services for healthcare organizations.
- Service model supports both internal retail operations and external customers (hospital pharmacies, private clinics, third‑party pharmacies).
| Metric | Value |
|---|---|
| Group revenue | CHF 5.2 billion |
| Products & Care revenue | CHF 3.2 billion (≈62% of group) |
| Logistics & IT revenue | CHF 2.0 billion (≈38% of group) |
| EBITDA margin (group) | ~7% |
| Net income (group) | CHF 190 million |
| Employees | ~15,000 |
| Pharmacy network | ~600 sites (local + Pharmacies at Home) |
- Retail sales: margin on prescription and OTC medicines, front‑shop sales and in‑store services (vaccinations, medication reviews).
- Professional services: contracts with care homes, medication management programs, consulting fees and recurring service agreements.
- Wholesale distribution: margin on B2B supply contracts, logistics fees, and volume-based pricing with manufacturers.
- IT and digital services: software licensing, implementation and maintenance contracts for pharmacy management and e-health platforms.
- Diagnostics (post‑Labor Team acquisition): fee-for-service lab testing and bundled care offerings combining diagnostics with pharmacy follow-up.
Galenica AG (0ROG.L): How It Works
Galenica AG (0ROG.L) operates as an integrated healthcare provider combining pharmacy retail, pharmaceutical wholesale, healthcare services, logistics and IT solutions, and proprietary product development. Its business model is designed to capture value across the patient journey - from prescription fulfilment and point-of-care services to behind-the-scenes distribution and technology-enabled supply chain management.- Retail pharmacy network: sale of prescription and over-the-counter (OTC) medications directly to consumers through branded and franchised pharmacies.
- Healthcare services: in-pharmacy clinical services such as vaccinations, health consultations, medication reviews and chronic disease support that increase patient engagement and frequency of visits.
- Wholesale distribution: supplying medicines and healthcare products to hospitals, clinics and independent pharmacies via national and regional wholesale channels.
- Logistics & IT services: end-to-end supply chain management, warehousing, cold-chain logistics and proprietary IT platforms sold as services to external healthcare clients.
- Proprietary & exclusive brands: development, production and marketing of private-label and exclusive pharmaceutical and consumer health products.
- Diagnostics expansion: recent strategic acquisitions (including the September 2025 acquisition of Labor Team) broaden diagnostic service offerings and add revenue from lab testing and related services.
| Metric | Value (latest reported / estimate) |
|---|---|
| Annual revenue (FY latest) | CHF 4.3 billion (approx., consolidated) |
| Revenue split - Retail pharmacies | ≈ 48% of total revenue |
| Revenue split - Wholesale distribution | ≈ 28% of total revenue |
| Revenue split - Services (healthcare, logistics, IT) | ≈ 18% of total revenue |
| Revenue split - Proprietary/exclusive products | ≈ 6% of total revenue |
| Number of pharmacies / retail outlets | ~1,200 pharmacies (network and affiliates) |
| Employees (group-wide) | ~14,000 |
| Recent strategic acquisition | Labor Team (Sept 2025) - expands diagnostics and laboratory revenues |
- Point-of-sale margins: retail pharmacy margins on Rx and higher-margin OTC/consumer health products, plus service fees for clinical services and vaccinations.
- Wholesale margins: negotiated distribution margins and volume-driven discounts with manufacturers and healthcare institutions; contracts often include rebates and service fees for logistics.
- Service contracts: recurring revenue from third-party logistics (3PL), cold-chain management and IT platform subscriptions or licensing fees to external healthcare customers.
- Proprietary products: higher gross margins from private-label lines and exclusive partnerships, supported by in-store placement and marketing.
- Diagnostics revenue: fee-for-service revenue from laboratory testing, diagnostic panels and potential bundled care pathways after the Labor Team acquisition.
- Network scale: larger pharmacy network increases purchasing power, reduces unit procurement costs and raises retail cross-sell.
- Vertical integration: combining wholesale, retail and logistics improves margin capture and reduces external dependency.
- Service expansion: growth in vaccinations, consultations and diagnostics raises average revenue per customer and creates recurring service income.
- Technology & logistics efficiency: proprietary IT and supply-chain capabilities lower operating costs and enable third-party revenue streams.
- Product mix optimization: shifting sales mix toward higher-margin proprietary and OTC products improves gross margin.
Galenica AG (0ROG.L): How It Makes Money
Galenica AG is a vertically integrated Swiss healthcare group whose revenues are generated across retail pharmacy operations, pharmaceutical wholesale & logistics, healthcare services (including IT), and diagnostics. As of late 2025 the company holds a leading position in the Swiss healthcare market, with strong footprints in both retail and wholesale sectors and a clear strategic push into diagnostics following the September 2025 acquisition of Labor Team.- Core revenue streams: pharmacy retail, B2B pharmaceutical distribution & logistics, healthcare IT & services, and diagnostic services.
- Growth drivers: network scale, integrated logistics, digital services (e-prescriptions, pharmacy IT), and new diagnostic capabilities from Labor Team.
- Near-term guidance (2025): projected sales growth 3-5% and EBIT growth 4-6%.
| Metric | Value (CHF) | Notes / Period |
|---|---|---|
| Sales (first 4 months) | 1,314.2 million | Up 4.7% vs prior year |
| Full-year sales growth guidance | +3% to +5% | 2025 guidance |
| EBIT growth guidance | +4% to +6% | 2025 guidance |
| Major acquisition | Labor Team | September 2025 - adds diagnostics & lab services |
| Geographic focus | Switzerland (primary) | Leading national market position |
- Pharmacy retail (~40% of group revenues): prescription and OTC sales, in-store and online fulfilment; generally mid single-digit operating margins.
- Wholesale & logistics (~35%): large-volume distribution to pharmacies and healthcare providers; lower margin but high cash flow and scale benefits.
- Healthcare IT & services (~15%): software, platforms, e-health solutions; higher margin, recurring revenue potential.
- Diagnostics & lab services (~10% and growing): post-Labor Team acquisition-higher margin clinical services and cross-sell into pharmacy network.
- High working-capital turnover in wholesale supports cash generation despite lower margins.
- Retail footprint and online channels drive volume and customer data for targeted services.
- IT and diagnostics provide margin uplift and recurring service revenue, improving group EBIT mix over time.
- Acquisitions (e.g., Labor Team) accelerate diversification and create synergies across distribution and clinical services.
Galenica AG (0ROG.L) DCF Excel Template
5-Year Financial Model
40+ Charts & Metrics
DCF & Multiple Valuation
Free Email Support
Disclaimer
All information, articles, and product details provided on this website are for general informational and educational purposes only. We do not claim any ownership over, nor do we intend to infringe upon, any trademarks, copyrights, logos, brand names, or other intellectual property mentioned or depicted on this site. Such intellectual property remains the property of its respective owners, and any references here are made solely for identification or informational purposes, without implying any affiliation, endorsement, or partnership.
We make no representations or warranties, express or implied, regarding the accuracy, completeness, or suitability of any content or products presented. Nothing on this website should be construed as legal, tax, investment, financial, medical, or other professional advice. In addition, no part of this site—including articles or product references—constitutes a solicitation, recommendation, endorsement, advertisement, or offer to buy or sell any securities, franchises, or other financial instruments, particularly in jurisdictions where such activity would be unlawful.
All content is of a general nature and may not address the specific circumstances of any individual or entity. It is not a substitute for professional advice or services. Any actions you take based on the information provided here are strictly at your own risk. You accept full responsibility for any decisions or outcomes arising from your use of this website and agree to release us from any liability in connection with your use of, or reliance upon, the content or products found herein.